# A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

> **NCT02811822** · PHASE1 · COMPLETED · sponsor: **GlycoMimetics Incorporated** · enrollment: 10 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** GMI-1271

## Key facts

- **NCT ID:** NCT02811822
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811822, "A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02811822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*